206 related articles for article (PubMed ID: 38381366)
1. Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma.
Pak C; Yoon S; Lee JL; Yun T; Park I
Curr Oncol Rep; 2024 Apr; 26(4):307-317. PubMed ID: 38381366
[TBL] [Abstract][Full Text] [Related]
2. Current Prospects for Adrenocortical Carcinoma Pharmacotherapy.
Ławnicka H
Recent Pat Anticancer Drug Discov; 2023; 18(1):29-37. PubMed ID: 36482727
[TBL] [Abstract][Full Text] [Related]
3. The challenge of developmental therapeutics for adrenocortical carcinoma.
Costa R; Carneiro BA; Tavora F; Pai SG; Kaplan JB; Chae YK; Chandra S; Kopp PA; Giles FJ
Oncotarget; 2016 Jul; 7(29):46734-46749. PubMed ID: 27102148
[TBL] [Abstract][Full Text] [Related]
4. Molecular markers and targeted therapies for adrenocortical carcinoma.
Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
[TBL] [Abstract][Full Text] [Related]
5. Management of Adrenocortical Carcinoma.
Jasim S; Habra MA
Curr Oncol Rep; 2019 Feb; 21(3):20. PubMed ID: 30798468
[TBL] [Abstract][Full Text] [Related]
6. Adrenocortical Carcinoma Steroid Profiles:
Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
[TBL] [Abstract][Full Text] [Related]
7. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs for the treatment of adrenocortical carcinoma.
Sukrithan V; Husain M; Kirschner L; Shah MH; Konda B
Expert Opin Emerg Drugs; 2021 Jun; 26(2):165-178. PubMed ID: 33896321
[No Abstract] [Full Text] [Related]
9. Current Status and Future Targeted Therapy in Adrenocortical Cancer.
Alyateem G; Nilubol N
Front Endocrinol (Lausanne); 2021; 12():613248. PubMed ID: 33732213
[TBL] [Abstract][Full Text] [Related]
10. 5th International ACC Symposium: An Outlook to Current and Future Research on the Biology of Adrenocortical Carcinoma: Diagnostic and Therapeutic Applications.
Lalli E; Sasano H
Horm Cancer; 2016 Feb; 7(1):44-8. PubMed ID: 26666256
[TBL] [Abstract][Full Text] [Related]
11. Adrenocortical carcinoma: current treatment options.
De Filpo G; Mannelli M; Canu L
Curr Opin Oncol; 2021 Jan; 33(1):16-22. PubMed ID: 33186181
[TBL] [Abstract][Full Text] [Related]
12. The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature.
Brabo EP; Moraes AB; Neto LV
J Endocrinol Invest; 2020 Nov; 43(11):1531-1542. PubMed ID: 32468513
[TBL] [Abstract][Full Text] [Related]
13. Update on adrenocortical carcinoma management and future directions.
Varghese J; Habra MA
Curr Opin Endocrinol Diabetes Obes; 2017 Jun; 24(3):208-214. PubMed ID: 28277340
[TBL] [Abstract][Full Text] [Related]
14. New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma (Review).
Stigliano A; Cerquetti L; Lardo P; Petrangeli E; Toscano V
Oncol Rep; 2017 Mar; 37(3):1301-1311. PubMed ID: 28184938
[TBL] [Abstract][Full Text] [Related]
15. Advanced Adrenocortical Carcinoma: Current Perspectives on Medical Treatment.
Araújo AN; Bugalho MJ
Horm Metab Res; 2021 May; 53(5):285-292. PubMed ID: 33962475
[TBL] [Abstract][Full Text] [Related]
16. The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma.
Grisanti S; Cosentini D; Laganà M; Volta AD; Palumbo C; Massimo Tiberio GA; Sigala S; Berruti A
Future Oncol; 2020 Dec; 16(36):3017-3020. PubMed ID: 32857613
[No Abstract] [Full Text] [Related]
17. Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies.
Lerario AM; Mohan DR; Hammer GD
Endocr Rev; 2022 Nov; 43(6):1051-1073. PubMed ID: 35551369
[TBL] [Abstract][Full Text] [Related]
18. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.
Kroiss M; Megerle F; Kurlbaum M; Zimmermann S; Wendler J; Jimenez C; Lapa C; Quinkler M; Scherf-Clavel O; Habra MA; Fassnacht M
J Clin Endocrinol Metab; 2020 May; 105(5):1461-8. PubMed ID: 31900481
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
[TBL] [Abstract][Full Text] [Related]
20. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]